Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on March 22, 2022. The report addresses a corporate governance event involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial statements.
Material Changes
On March 22, 2022, Michael G. Kauffman, M.D., Ph.D., resigned from the Board of Directors, effective immediately. The Company stated that the resignation is not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary on financial guidance, outlook, or specific risks beyond the disclosure of the director's departure. No unusual items or contingencies were reported in this document.
Key Facts for Investor Verification
- Michael G. Kauffman, M.D., Ph.D., resigned from the Board of Directors effective March 22, 2022.
- The resignation was not caused by any disagreement with the Company.
- The report was signed by Michael Mano, Senior Vice President, General Counsel and Secretary, on March 28, 2022.